open access

Vol 71, No 3 (2020)
Original Paper
Published online: 2020-05-12
Submitted: 2019-12-27
Accepted: 2020-03-27
Get Citation

Identification of related long non-coding RNAs and mRNAs in subclinical hypothyroidism complicated with type 2 diabetes by transcriptome analysis — a preliminary study

Qiang Jiang, Lizhi Sun, Yong Lu, Shuyi Han, Lulu Hou, Kai Lou, Jianting Li, Lulu Wang, Shuguang Pang
DOI: 10.5603/EP.a2020.0025
·
Endokrynologia Polska 2020;71(3):213-226.

open access

Vol 71, No 3 (2020)
Original Paper
Published online: 2020-05-12
Submitted: 2019-12-27
Accepted: 2020-03-27

Abstract

Introduction: The pathology mechanism of subclinical hypothyroidism and subclinical hypothyroidism complicated with type 2 diabetes remained uncertain. We aimed to find potential related long non-coding RNAs (lncRNAs) and mRNAs in the above diseases.

Material and methods: Transcriptome sequencing was performed in three patients with subclinical hypothyroidism (S), three patients with subclinical hypothyroidism complicated with type 2 diabetes (SD), and three healthy controls (N). Differentially expressed mRNAs (DEmRNAs) and differentially expressed lncRNAs (DElncRNAs) were screened in S vs. N, SD vs. N, and SD vs. S group, and the nearby and co-expressed DEmRNAs of DElncRNAs were screened in S vs. N and SD vs. N. Moreover, functional analysis of DEmRNAs was then performed by Metascape.

Results: In total, 465, 1058, and 943 DEmRNAs were obtained in S vs. N, SD vs. N, SD vs. S, respectively, and 191 overlapping genes were obtained in S vs. N and SD vs. N group. Among which, LAIR2, PNMA6A, and SFRP2 were deduced to be involved in subclinical hypothyroidism, and GPR162, APOL4, and ANK1 were deduced to be associated with subclinical hypothyroidism complicated with type 2 diabetes. A total of 50, 100, and 88 DElncRNAs were obtained in S vs. N, SD vs. N and SD vs. S, respectively. Combining with the interaction network of DElncRNA-DEmRNA, PAX8-AS1, co-expressed with KIR3DL1, was identified to function in subclinical hypothyroidism, and JHDM1D-AS1, co-expressed with ANK1, was deduced to play a role in subclinical hypothyroidism complicated with type 2 diabetes.

Conclusions: Dysfunctional lncRNAs and mRNAs may be involved in the development of subclinical hypothyroidism and subclinical hypothyroidism complicated with type 2 diabetes. 

Abstract

Introduction: The pathology mechanism of subclinical hypothyroidism and subclinical hypothyroidism complicated with type 2 diabetes remained uncertain. We aimed to find potential related long non-coding RNAs (lncRNAs) and mRNAs in the above diseases.

Material and methods: Transcriptome sequencing was performed in three patients with subclinical hypothyroidism (S), three patients with subclinical hypothyroidism complicated with type 2 diabetes (SD), and three healthy controls (N). Differentially expressed mRNAs (DEmRNAs) and differentially expressed lncRNAs (DElncRNAs) were screened in S vs. N, SD vs. N, and SD vs. S group, and the nearby and co-expressed DEmRNAs of DElncRNAs were screened in S vs. N and SD vs. N. Moreover, functional analysis of DEmRNAs was then performed by Metascape.

Results: In total, 465, 1058, and 943 DEmRNAs were obtained in S vs. N, SD vs. N, SD vs. S, respectively, and 191 overlapping genes were obtained in S vs. N and SD vs. N group. Among which, LAIR2, PNMA6A, and SFRP2 were deduced to be involved in subclinical hypothyroidism, and GPR162, APOL4, and ANK1 were deduced to be associated with subclinical hypothyroidism complicated with type 2 diabetes. A total of 50, 100, and 88 DElncRNAs were obtained in S vs. N, SD vs. N and SD vs. S, respectively. Combining with the interaction network of DElncRNA-DEmRNA, PAX8-AS1, co-expressed with KIR3DL1, was identified to function in subclinical hypothyroidism, and JHDM1D-AS1, co-expressed with ANK1, was deduced to play a role in subclinical hypothyroidism complicated with type 2 diabetes.

Conclusions: Dysfunctional lncRNAs and mRNAs may be involved in the development of subclinical hypothyroidism and subclinical hypothyroidism complicated with type 2 diabetes. 

Get Citation

Keywords

 subclinical hypothyroidism; subclinical hypothyroidism complicated with type 2 diabetes; lncRNAs; mRNAs

Supplementary Files (1)
Supplementary Tables
Download
15KB
About this article
Title

Identification of related long non-coding RNAs and mRNAs in subclinical hypothyroidism complicated with type 2 diabetes by transcriptome analysis — a preliminary study

Journal

Endokrynologia Polska

Issue

Vol 71, No 3 (2020)

Pages

213-226

Published online

2020-05-12

DOI

10.5603/EP.a2020.0025

Bibliographic record

Endokrynologia Polska 2020;71(3):213-226.

Keywords

 subclinical hypothyroidism
subclinical hypothyroidism complicated with type 2 diabetes
lncRNAs
mRNAs

Authors

Qiang Jiang
Lizhi Sun
Yong Lu
Shuyi Han
Lulu Hou
Kai Lou
Jianting Li
Lulu Wang
Shuguang Pang

References (37)
  1. Navarro PV, Pinilla EI, España AG, et al. Prevalence of hypothyroidism in major psychiatric disorders in hospitalised patients in Montserrat Hospital during the period March to October 2010. Rev Colomb Psiquiatr (English ed.). 2017; 46(3): 140–146.
  2. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4): 526–534.
  3. Gillett M. Subclinical Hypothyroidism: Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management. Clin Biochem Rev. 2004; 25(3): 191–194.
  4. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291(2): 228–238.
  5. Fatourechi V. Subclinical hypothyroidism and subclinical hyperthyroidism. Expert Rev Endocrinol Metab. 2010; 5(3): 359–373.
  6. Auer R, Rodondi N. Relationship Between Subclinical Thyroid Dysfunction and Heart Failure and Mortality. In: Iervasi G, Pingitore A. ed. Thyroid and Heart Failure: From Pathophysiology to Clinics. Springer, Milan 2009: 167.
  7. Loh HH, Lim LL, Yee A, et al. Association between subclinical hypothyroidism and depression: an updated systematic review and meta-analysis. BMC Psychiatry. 2019; 19(1): 12.
  8. Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf). 1995; 43(4): 445–449.
  9. Negro R, Stagnaro-Green A. Diagnosis and management of subclinical hypothyroidism in pregnancy. BMJ. 2014; 349: g4929.
  10. Hecht A, Gershberg H. Diabetes mellitus and primary hypothyroidism. Metabolism. 1968; 17(2): 108–113.
  11. Cho JHo, Kim HoJ, Lee JHo, et al. Poor glycemic control is associated with the risk of subclinical hypothyroidism in patients with type 2 diabetes mellitus. Korean J Intern Med. 2016; 31(4): 703–711.
  12. Hon CC, Ramilowski JA, Harshbarger J, et al. An atlas of human long non-coding RNAs with accurate 5' ends. Nature. 2017; 543(7644): 199–204.
  13. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25(18): 1915–1927.
  14. Kornienko AE, Guenzl PM, Barlow DP, et al. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013; 11: 59.
  15. Alfadda AA, Benabdelkamel H, Masood A, et al. Differences in the Plasma Proteome of Patients with Hypothyroidism before and after Thyroid Hormone Replacement: A Proteomic Analysis. Int J Mol Sci. 2018; 19(1).
  16. Simone R, Pesce G, Antola P, et al. Serum LAIR-2 is increased in autoimmune thyroid diseases. PLoS One. 2013; 8(5): e63282.
  17. Kress E, Rezza A, Nadjar J, et al. The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. J Biol Chem. 2009; 284(2): 1234–1241.
  18. Zuo H, Gandhi M, Edreira MM, et al. Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 2010; 70(4): 1389–1397.
  19. Poleev A, Fickenscher H, Mundlos S, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development. 1992; 116(3): 611–623.
  20. Placzkowski KA, Reddi HV, Grebe SKG, et al. The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. PPAR Res. 2008; 2008: 672829.
  21. Han J, Zhou W, Jia M, et al. Expression quantitative trait loci in long non-coding RNA PAX8-AS1 are associated with decreased risk of cervical cancer. Mol Genet Genomics. 2016; 291(4): 1743–1748.
  22. Matsushita T, Ashikawa K, Yonemoto K, et al. Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. Hum Mol Genet. 2010; 19(6): 1137–1146.
  23. de Toro-Martín J, Guénard F, Rudkowska I, et al. A common variant in ARHGEF10 alters delta-6 desaturase activity and influence susceptibility to hypertriglyceridemia. J Clin Lipidol. 2018; 12(2): 311–320.e3.
  24. Lundberg M, Krogvold L, Kuric E, et al. Expression of Interferon-Stimulated Genes in Insulitic Pancreatic Islets of Patients Recently Diagnosed With Type 1 Diabetes. Diabetes. 2016; 65(10): 3104–3110.
  25. Zhi D, Sun C, Sedimbi SK, et al. Killer cell immunoglobulin-like receptor along with HLA-C ligand genes are associated with type 1 diabetes in Chinese Han population. Diabetes Metab Res Rev. 2011; 27(8): 872–877.
  26. van der Slik AR, Koeleman BPC, Verduijn W, et al. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003; 52(10): 2639–2642.
  27. Li Lu, Pan Z, Yang Xi. Key genes and co-expression network analysis in the livers of type 2 diabetes patients. J Diabetes Investig. 2019; 10(4): 951–962.
  28. Russell MA, Redick SD, Blodgett DM, et al. HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of Islet β-Cells From Donors With Type 1 Diabetes. Diabetes. 2019; 68(5): 988–1001.
  29. Heon KS, Joo PY, Jin GM, et al. A genome-wide association study on thyroid function and anti-thyroid peroxidase antibodies in Koreans. Hum Mol Genet. 2014; 23(16): 4433–4442.
  30. Rasche A, Al-Hasani H, Herwig R. Meta-analysis approach identifies candidate genes and associated molecular networks for type-2 diabetes mellitus. BMC Genomics. 2008; 9: 310.
  31. Yan R, Lai S, Yang Y, et al. A novel type 2 diabetes risk allele increases the promoter activity of the muscle-specific small ankyrin 1 gene. Sci Rep. 2016; 6: 25105.
  32. Duchateau PN, Movsesyan I, Yamashita S, et al. Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. J Lipid Res. 2000; 41(8): 1231–1236.
  33. Collares CVA, Evangelista AF, Xavier DJ, et al. Transcriptome meta-analysis of peripheral lymphomononuclear cells indicates that gestational diabetes is closer to type 1 diabetes than to type 2 diabetes mellitus. Mol Biol Rep. 2013; 40(9): 5351–5358.
  34. Fox ER, Young JH, Li Y, et al. International Consortium for Blood Pressure Genome-wide Association Studies (ICBP-GWAS). Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet. 2011; 20(11): 2273–2284.
  35. Ruiz-Hernández A, Sánchez-Muñoz F, Rodriguez J, et al. Expression of orphan receptors GPR22 and GPR162 in streptozotocin-induced diabetic rats. J Recept Signal Transduct Res. 2015; 35(1): 46–53.
  36. Kondo A, Nonaka A, Shimamura T, et al. Long Noncoding RNA JHDM1D-AS1 Promotes Tumor Growth by Regulating Angiogenesis in Response to Nutrient Starvation. Mol Cell Biol. 2017; 37(18).
  37. Inagaki T, Tachibana M, Magoori K, et al. Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice. Genes Cells. 2009; 14(8): 991–1001.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl